At a glance
- What the study gets you
- Access to the study treatment being tested
- Type of study
- Interventional (receives a drug or procedure)
- Time in hospital
- In-person visits at study sites — visit count not specified by the sponsor
- Drug or intervention
- mRNA-3927 (biological)
- How long the study runs
- Study runs about 121 months (dates as stated)
- About the drug or intervention
- mRNA-3927 — biological: mRNA-3927 dispersion for IV infusion
- Patient visit burden
- Not specified by the sponsor
In plain English
This study looks at the long-term safety and how well the study medicine mRNA-3927 works in people with propionic acidemia, a rare inherited condition. It is only open to people who took part in an earlier study called mRNA-3927-P101. It is run by ModernaTX, Inc.
Who can take part
- You took part in the earlier study called mRNA-3927-P101.
- You finished the end-of-treatment visit in that study and start this study within about 14 days (plus or minus 3 days) of your last dose of mRNA-3927 in that study.
Who may not be able to
- The study doctor does not think you would benefit from continuing to have mRNA-3927.
- You have any health problem or unusual test result that, in the study doctor's view, could make taking part more risky for you.
- You have had a liver and/or kidney transplant.
What taking part involves
- • Continuing to receive the study medicine mRNA-3927.
Time commitment: Not stated — ask the trial team about how many visits there are, how long the study lasts, and what taking part involves.
Plain-English summary (AI-generated) from registry data. Not eligibility advice — only the trial team can confirm whether you can take part. Use the eligibility checker to see how your health profile matches this trial.
- Type of study
- Testing a treatment
- Ages
- 1 Year and over
- Who
- All
- Number of participants
- 50
- Started
- 2021-11-09
- Last checked
- 2026-03
Plain English Summary
What is this study?
- • Testing a new treatment for propionic acidemia
- • Phase1/Phase2 - 50 participants
- • The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103)
Who can take part?
- • Ages 1 Year and over
- • Diagnosed with propionic acidemia
Where?
- • Manchester - Willink Biochemical Genetics Unit - Manchester
- • Birmingham - University Hospital Birmingham NHS Foundation Trust
- • Birmingham - Birmingham Women's and Children's NHS Foundation Trust
- • London - Great Ormond Street Hospital for Children NHS Foundation Trust
This is a simplified summary. Always discuss with your doctor before making any decisions.
About This Trial
The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).
More detail
The study will assess long-term safety of mRNA-3927. Participants with PA who were previously enrolled and completed the end-of-treatment (EOT)/early termination (ET) visit of the mRNA-3927-P101 study will have the option to enroll into this extension study provided all eligibility criteria have been met. The study will include 2 periods: 1) Treatment Period and 2) Follow-up Period (90 days after the EOT visit). All participants will enter the study receiving mRNA-3927 at the same dose and at the same dosing interval last received in the mRNA-3927-P101 study.
How this trial compares with your answers
Answer 2 more questions to improve match
What we know so far
Still need:
- • Tell us your age for better matching
- • Tell us your sex for better matching
Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.
Eligibility at a Glance
Key info
- Age: 1 Year and over
- Who can join: All genders
What the study is looking for
- ✓Participated in Study mRNA-3927-P101.
Who cannot take part
- ✗Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
- ✗Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the...
- ✗History of liver and/or kidney transplant.
See the full criteria
Where Is This Study? (4 UK sites)
Willink Biochemical Genetics Unit - Manchester
Manchester M13 9WL, United Kingdom
University Hospital Birmingham NHS Foundation Trust
Birmingham B15 2TH, United Kingdom
Birmingham Women's and Children's NHS Foundation Trust
Birmingham B4 6NH, United Kingdom
Great Ormond Street Hospital for Children NHS Foundation Trust
London WC1N 3JH, United Kingdom
Main Email: Research.Governance@gosh.nhs.uk
Research.Governance@gosh.nhs.uk0207 905 2700How to Get in Touch
Moderna WeCare Team
Sponsor contactCONTACT